Suppressive effects of 3-bromopyruvate on the proliferation and the motility of hepatocellular carcinoma cells

Tomizawa,Minoru; Shinozaki,Fuminobu; Motoyoshi,Yasufumi; Sugiyama,Takao; Yamamoto,Shigenori; Ishige,Naoki

doi:10.3892/or.2015.4370

Suppressive effects of 3-bromopyruvate on the proliferation and the motility of hepatocellular carcinoma cells

Authors:
- Minoru Tomizawa
- Fuminobu Shinozaki
- Yasufumi Motoyoshi
- Takao Sugiyama
- Shigenori Yamamoto
- Naoki Ishige
View Affiliations

Affiliations: Department of Gastroenterology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan, Department of Radiology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan, Department of Neurology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan, Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan, Department of Pediatrics, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan, Department of Neurosurgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan
Published online on: November 2, 2015 https://doi.org/10.3892/or.2015.4370
Pages: 59-63

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The compound 3-bromopyruvate (3BP) is an analogue of pyruvate, which is the final product of glycolysis that enters the citric acid cycle. The present study aimed to investigate the suppressive effects of 3BP on the proliferation and motility of hepatocellular carcinoma (HCC) cells. HLF and PLC/PRF/5 cells were cultured with 3BP and subjected to an MTS assay. Apoptosis was analyzed by hematoxylin and eosin staining. Cell motility was analyzed using a scratch assay. Real-time quantitative polymerase chain reaction (PCR) was performed to determine the expression levels of cyclin D1 and matrix metalloproteinase (MMP)9. Proliferation of both cell lines was significantly suppressed by 3BP at 100 µM (P<0.05). The expression level of cyclin D1 was decreased after 3BP treatment at 100 µM in both cell lines (P<0.05). Pyknotic nuclei were observed in the cells cultured with 3BP at 100 µM. These results revealed that 3BP suppressed cell proliferation, decreased the expression of cyclin D1, and induced apoptosis in HCC cells. 3BP significantly suppressed motility in both cell lines (P<0.05). The expression level of MMP9 was significantly decreased (P<0.05). 3BP suppressed the proliferation and motility of HCC cells by decreasing the expression of cyclin D1 and MMP9.

View Figures

View References

1	Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF and Carrillo-Pérez DL: Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol. 7:362–376. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lencioni R, Petruzzi P and Crocetti L: Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 30:3–11. 2013. View Article : Google Scholar :
3	Kim HY and Park JW: Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: Past, present, and future. Liver Cancer. 3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
4	Chen C and Wang G: Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015. View Article : Google Scholar : PubMed/NCBI
5	Vaitheesvaran B, Xu J, Yee J, Q-Y L, Go VL, Xiao GG and Lee WN: The Warburg effect: A balance of flux analysis. Metabolomics. 11:787–796. 2015. View Article : Google Scholar : PubMed/NCBI
6	Jang M, Kim SS and Lee J: Cancer cell metabolism: Implications for therapeutic targets. Exp Mol Med. 45:e452013. View Article : Google Scholar : PubMed/NCBI
7	Granja S, Pinheiro C, Reis RM, Martinho O and Baltazar F: Glucose addiction in cancer therapy: Advances and drawbacks. Curr Drug Metab. 16:221–242. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ngo DC, Ververis K, Tortorella SM and Karagiannis TC: Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol Biol rep. 42:819–823. 2015. View Article : Google Scholar : PubMed/NCBI
9	Shoshan MC: 3-Bromopyruvate: Targets and outcomes. J Bioenerg Biomembr. 44:7–15. 2012. View Article : Google Scholar : PubMed/NCBI
10	Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, et al: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 29:4909–4918. 2009.
11	Cardaci S, Desideri E and Ciriolo MR: Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr. 44:17–29. 2012. View Article : Google Scholar : PubMed/NCBI
12	Davies B and Fried M: The L19 ribosomal protein gene (RPL19): Gene organization, chromosomal mapping, and novel promoter region. Genomics. 25:372–380. 1995. View Article : Google Scholar : PubMed/NCBI
13	Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: Past and present. Expert Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar : PubMed/NCBI
14	Vandooren J, Van den Steen PE and Opdenakker G: Biochemistry and molecular biology of gelatinase B or matrix metallopro-teinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol. 48:222–272. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R and Vali M: 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res. 30:923–935. 2010.PubMed/NCBI
16	Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, Vali M and Geschwind JF: Human hepatocellular carcinoma in a mouse model: Assessment of tumor response to percutaneous ablation by using glyceral-dehyde-3-phosphate dehydrogenase antagonists. Radiology. 262:834–845. 2012. View Article : Google Scholar : PubMed/NCBI
17	Liu XH, Zheng XF and Wang YL: Inhibitive effect of 3-bromo-pyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J (Engl). 122:1681–1685. 2009.
18	Feng X, Wang P, Liu Q, Zhang T, Mai B and Wang X: Glycolytic inhibitors 2-deoxyglucose and 3-bromopyruvate synergize with photodynamic therapy respectively to inhibit cell migration. J Bioenerg Biomembr. 47:189–197. 2015. View Article : Google Scholar : PubMed/NCBI
19	Jae HJ, Chung JW, Park HS, Lee MJ, Lee KC, Kim HC, Yoon JH, Chung H and Park JH: The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: In vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. Korean J Radiol. 10:596–603. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yu SJ, Yoon JH, Yang JI, Cho EJ, Kwak MS, Jang ES, Lee JH, Kim YJ, Lee HS and Kim CY: Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting Er stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr. 44:101–115. 2012. View Article : Google Scholar : PubMed/NCBI
21	Liapi E and Geschwind JF: Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 17:405–406. 2010. View Article : Google Scholar
22	Geschwind JF, Ko YH, Torbenson MS, Magee C and Pedersen PL: Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 62:3909–3913. 2002.PubMed/NCBI